Clinical and genetic spectrum of factor XII deficiency in the Han population of East China.

IF 3.4 2区 医学 Q2 GENETICS & HEREDITY
Fei Xu, Langyi Qin, Anqing Zou, Lingling Hou, Mingshan Wang, Bile Chen
{"title":"Clinical and genetic spectrum of factor XII deficiency in the Han population of East China.","authors":"Fei Xu, Langyi Qin, Anqing Zou, Lingling Hou, Mingshan Wang, Bile Chen","doi":"10.1186/s13023-024-03404-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Factor XII (FXII or F12) deficiency is a rare inherited disorder, typically lacking haemorrhagic symptoms. There is limited literature exists on FXII deficiency and mutations within the Chinese population. This study aimed to characterize the spectrum of F12 gene mutations in a Chinese cohort and to investigate the relationship between FXII mutations and clinical phenotypes.</p><p><strong>Methods: </strong>Genetic and clinical data from 51 unrelated probands with FXII deficiency, along with their families, were meticulously collected and analysed.</p><p><strong>Results: </strong>Genetic analysis revealed that 94.1% of probands carried genetic defects, with 29 mutations pinpointed in the F12 gene. Of these, 18 mutations were previously reported for the first time by our research group, including c.303_304delCA, c.1078G > A, c.1285 C > T, among others. Of the mutations, 17 are missense, constituting 58.6% of the total. Additionally, 11 are deletions or insertions, of which 8 result in frameshifts, while the remaining one is a nonsense mutation. These mutations were predominantly concentrated in two crucial regions: the catalytic domain and the kringle domain. The most frequently observed mutations were c.1681G > A, closely followed by c.1561G > A and c.1078G > A, indicating a dominance among these mutations. Additionally, a prevalent polymorphism at position 46 was observed in the majority of probands, with 47.1% having the 46T/T genotype and 13.7% having the 46 C/T genotype, which may potentially impact FXII activity. The broad spectrum of asymptomatic FXII deficiency observed within the Han population of East China.</p><p><strong>Conclusions: </strong>We speculate on the potential impact of recurrent mutations on the efficacy of new drugs being developed to target FXII for thrombosis prevention and treatment. Furthermore, it is important to explore their influence on FXII-related pathways beyond the activation of the contact pathway in the coagulation cascade.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-024-03404-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Factor XII (FXII or F12) deficiency is a rare inherited disorder, typically lacking haemorrhagic symptoms. There is limited literature exists on FXII deficiency and mutations within the Chinese population. This study aimed to characterize the spectrum of F12 gene mutations in a Chinese cohort and to investigate the relationship between FXII mutations and clinical phenotypes.

Methods: Genetic and clinical data from 51 unrelated probands with FXII deficiency, along with their families, were meticulously collected and analysed.

Results: Genetic analysis revealed that 94.1% of probands carried genetic defects, with 29 mutations pinpointed in the F12 gene. Of these, 18 mutations were previously reported for the first time by our research group, including c.303_304delCA, c.1078G > A, c.1285 C > T, among others. Of the mutations, 17 are missense, constituting 58.6% of the total. Additionally, 11 are deletions or insertions, of which 8 result in frameshifts, while the remaining one is a nonsense mutation. These mutations were predominantly concentrated in two crucial regions: the catalytic domain and the kringle domain. The most frequently observed mutations were c.1681G > A, closely followed by c.1561G > A and c.1078G > A, indicating a dominance among these mutations. Additionally, a prevalent polymorphism at position 46 was observed in the majority of probands, with 47.1% having the 46T/T genotype and 13.7% having the 46 C/T genotype, which may potentially impact FXII activity. The broad spectrum of asymptomatic FXII deficiency observed within the Han population of East China.

Conclusions: We speculate on the potential impact of recurrent mutations on the efficacy of new drugs being developed to target FXII for thrombosis prevention and treatment. Furthermore, it is important to explore their influence on FXII-related pathways beyond the activation of the contact pathway in the coagulation cascade.

华东地区汉族人群中 XII 因子缺乏症的临床和遗传谱。
背景:因子 XII(FXII 或 F12)缺乏症是一种罕见的遗传性疾病:因子 XII(FXII 或 F12)缺乏症是一种罕见的遗传性疾病,通常没有出血症状。有关中国人群中 FXII 缺乏症和基因突变的文献十分有限。本研究旨在描述中国人群中 F12 基因突变的范围,并调查 FXII 基因突变与临床表型之间的关系:方法:仔细收集并分析了51名无亲属关系的FXII缺乏症患者及其家属的基因和临床数据:结果:基因分析表明,94.1%的疑似患者存在基因缺陷,其中 29 个基因突变位于 F12 基因。其中,18 个突变是我们研究小组之前首次报道的,包括 c.303_304delCA、c.1078G > A、c.1285 C > T 等。在这些突变中,17 个是错义突变,占总数的 58.6%。此外,有 11 个是缺失或插入突变,其中 8 个导致了框架转换,剩下的一个是无义突变。这些突变主要集中在两个关键区域:催化结构域和环状结构域。最常见的突变是c.1681G > A,紧随其后的是c.1561G > A和c.1078G > A,表明这些突变占主导地位。此外,在大多数受试者中还观察到 46 位的多态性,47.1% 的受试者为 46T/T 基因型,13.7% 的受试者为 46 C/T 基因型,这可能会影响 FXII 的活性。在华东地区的汉族人群中观察到了广泛的无症状 FXII 缺乏症:我们推测,复发性突变可能会影响正在开发的以 FXII 为靶点的预防和治疗血栓的新药的疗效。此外,除了激活凝血级联中的接触途径外,探讨其对 FXII 相关途径的影响也很重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信